33.53
price up icon3.94%   1.27
after-market アフターアワーズ: 33.53
loading
前日終値:
$32.26
開ける:
$33.12
24時間の取引高:
1.44M
Relative Volume:
0.84
時価総額:
$5.35B
収益:
$705.14M
当期純損益:
$-453.90M
株価収益率:
-11.03
EPS:
-3.04
ネットキャッシュフロー:
$-551.29M
1週間 パフォーマンス:
-0.34%
1か月 パフォーマンス:
+20.18%
6か月 パフォーマンス:
-11.23%
1年 パフォーマンス:
-14.20%
1日の値動き範囲:
Value
$32.60
$33.94
1週間の範囲:
Value
$31.66
$33.94
52週間の値動き範囲:
Value
$23.95
$52.34

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1154)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
927
Name
Twitter
@ionispharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

IONS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
33.53 5.35B 705.14M -453.90M -551.29M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
439.37 128.45B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
575.63 65.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
560.90 40.09B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.19 35.67B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
233.25 27.44B 3.81B -644.79M -669.77M -6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-07 開始されました H.C. Wainwright Buy
2025-03-31 開始されました Redburn Atlantic Neutral
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
May 11, 2025

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential - Insider Monkey

May 11, 2025
pulisher
May 11, 2025

Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN

May 09, 2025
pulisher
May 06, 2025

Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

Ionis to host 2025 virtual Annual Meeting of Stockholders | IONS Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Ionis to host 2025 virtual Annual Meeting of Stockholders - Quantisnow

May 06, 2025
pulisher
May 05, 2025

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com

May 05, 2025
pulisher
May 05, 2025

Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com

May 05, 2025
pulisher
May 05, 2025

Oligonucleotide Delivery System Market Key Players Analysis - openPR.com

May 05, 2025
pulisher
May 05, 2025

Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN

May 05, 2025
pulisher
May 03, 2025

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View - MSN

May 03, 2025
pulisher
May 02, 2025

Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow

May 02, 2025
pulisher
May 02, 2025

Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates - simplywall.st

May 02, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts - Investing.com Australia

May 02, 2025
pulisher
May 02, 2025

Ionis Pharmaceuticals (IONS) Projects Revenue Growth with TRYNGO - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 02, 2025
pulisher
May 01, 2025

IONIS: Guggenheim Maintains Buy Rating but Lowers Price Target | - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals (IONS) Receives Price Target Boost from HC Wainwright | IONS Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Polycythemia vera Market: Epidemiology, Therapies, - openPR.com

May 01, 2025
pulisher
May 01, 2025

Ionis Earnings: Strong Commercial Launch of Tryngolza; Positive Long-Term Outlook - Morningstar

May 01, 2025
pulisher
May 01, 2025

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts - Benzinga

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals (IONS) Target Price Increased to $50 After Strong Q1 | IONS Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals Ups Revenue Forecast After Q1 Success - Finimize

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim | IONS Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlight - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

May 01, 2025
pulisher
May 01, 2025

Ionis Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks

May 01, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals: Q1 Earnings Snapshot - MySA

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals (IONS) Boosts 2025 Revenue Guidance and St - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge - Benzinga

Apr 30, 2025
pulisher
Apr 30, 2025

Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com India

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals (IONS) Q1 2025 Earnings: Revenue Surpasses - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis (IONS) Sees Strong Q1 Revenue with New Launches Fueling Gr - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Ionis reports first quarter 2025 financial results - BioSpace

Apr 30, 2025

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$67.75
price up icon 4.10%
$19.93
price up icon 2.94%
$33.35
price up icon 0.60%
$25.26
price up icon 5.43%
$97.27
price up icon 4.85%
biotechnology ONC
$233.25
price up icon 0.54%
大文字化:     |  ボリューム (24 時間):